Agoracom Blog Home

Posts Tagged ‘small cap’

« Older Entries
Newer Entries »

Hong-Kong listed H&H leads a $25.7M investment in ELSE Nutrition $BABY.ca $ABT $TSN $CAG

Posted by AGORACOM-JC at 7:17 AM on Tuesday, October 13th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

The global baby & adult nutrition company increases its strategic capital stake in ELSE to $9.75M via its subsidiary NewH2 Limited

  • NewH2 Limited, a subsidiary of Health and Happiness (H&H) International Holdings Limited, a Hong Kong Stock Exchange listed company (1112.HK) has increased their strategic investment in Else by C$4.0 million pursuant to a non-brokered private placement announced on September 15th.
  • With the completion this financing NewH2 owns 10,678,706 shares of the Company and 3,114,121 warrants, which will represent approximately 11.6% of the Company’s issued and outstanding common shares
  • Else intends to use the proceeds of the offering to market its novel, plant-based baby and toddler nutrition products in North America alongside new product development operations.

VANCOUVER, BC / October 13, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), a developer of plant-based alternatives to dairy-based baby nutrition, is announcing today that NewH2 Limited, a subsidiary of Health and Happiness (H&H) International Holdings Limited, a Hong Kong Stock Exchange listed company (1112.HK) has increased their strategic investment in Else by C$4.0 million pursuant to a non-brokered private placement announced on September 15th.

The Company intends to use the proceeds of the offering to market its novel, plant-based baby and toddler nutrition products in North America alongside new product development operations. Furthermore, the investment provides the Company with the ability to accelerate and increase its production and supply capabilities, increase marketing activities and introduce its product(s) in new territories globally.

“We are very excited to continue to expand our relationship with H&H. They have been an immensely valuable partner and we look forward to working with their team in new market regions. We hear regularly from families across the globe who are seeking a non-dairy nutrition alternative for their children and we are fortunate to have a global partner supporting our endeavours for introduction of our products to store shelves in North America and beyond,” said Ms. Hamutal Yitzhak, CEO and Co-Founder of Else.

Pursuant to the private placement the Company issued 2,224,111 (the “Units”) at a price of C$2.25 per Unit. Each Unit consisting of one common share and 0.50 share purchase warrants, with each whole warrant (a “Warrant”) entitling the holder to acquire one additional common share of the Company at an exercise price of C$3.25 per share for a period of thirty months from the closing date. With the completion this financing NewH2 owns 10,678,706 shares of the Company and 3,114,121 warrants, which will represent approximately 11.6% of the Company’s issued and outstanding common shares. The units issued will be subject to a 12 month hold period from date of closing.

The Company also pleased to announce that it has closed its previously announced upsized bought deal public offering, lead by Canaccord Genuity, of units (the “Units“) for ‎aggregate gross proceeds of CAD$20.7 million, including the exercise of the over-allotment option in full (the “Offering“). The Company issued ‎‎9,200,000 Units at a price of CAD$2.25 per Unit, each Unit consisting of one common share of the ‎Company (a “Share“) and one-half of one common share purchase warrant, with each whole warrant (a “Warrant“) ‎entitling the holder to purchase one Share at the price of CAD$3.25 per Share until October 6, 2022. ‎The Company has received approval from the TSX Venture Exchange (“TSXV“) to list the Warrants issued pursuant to the Offering, and the Warrants are posted for trading on the TSXV under the ticker symbol “BABY.WT” effective October 8, 2020.

Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com, and will soon be available on Amazon.com. Consumers can order single 22 oz cans and 4-packs.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For more information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director of Else Nutrition
Email: [email protected]
Telephone: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Else Nutrition Holdings Inc., Featured | Comments Off on Hong-Kong listed H&H leads a $25.7M investment in ELSE Nutrition $BABY.ca $ABT $TSN $CAG

Innocan $INNO.ca Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable #CBD $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:11 PM on Friday, October 9th, 2020
Innocan-Blog
  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Herzliya, Israel and Calgary, Alberta–(October 9, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that an animal study on mice, demonstrated a prolonged release of Cannabidiol (“CBD”) into the blood for at least three weeks after one administration. This study was conducted by The Hebrew University of Jerusalem, Israel based on Innocan’s licensed CBD loaded liposome platform technology (“LPT”) for injectable CBD.

The study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Berenholz, was conducted in The Hebrew University of Jerusalem laboratories on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT.

These results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration.

These results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Innocan Israel, a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of The Hebrew University of Jerusalem in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development is led by Professor Chezy Barenholz, head of the Membrane and Liposome research department at The Hebrew University, which was the inventor of over 55 patent families, two of which underlie Doxil® – an FDA approved drug for breast cancer treatment. This unique technology platform may be implemented for several indications such as epilepsy, pain relief, and different inflammation and central nervous system disorders. A patent was filed on this technology on October 7, 2019.

Professor Chezy Berenholz stated, ” I believe that the results of this animal study, showing the prolonged release of CBD into the blood stream is an extremely important major milestone. This may open a wide range of clinical applications which may allow for the maintenance of a certain level of CBD in the blood for a longer period of time which may also lead to improved patient’s compliance. If successful, this technology may be beneficial for various additional indications.”

Iris Bincovich, Innocan’s CEO, added, “As variety of studies demonstrates the effectiveness of cannabinoids in the treatment of various CNS conditions, this has the potential to address indication such as Epilepsy.”

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable #CBD $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Innocan Pharma $INNO.ca to Provide a Corporate Update via Livestream Video $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:10 PM on Thursday, October 8th, 2020
Innocan-Blog
  • Will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.
  • update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

Herzliya, Israel and Calgary, Alberta–(October 8, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that it will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.

The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

The YouTube livestream video will be available through livestream.innocanpharma.com

About Innocan

The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing Cannabidoil (“CBD”). Innocan Israel, a wholly owned subsidiary of the Company, and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , ,
Posted in Innocan Pharma Corporation | Comments Off on Innocan Pharma $INNO.ca to Provide a Corporate Update via Livestream Video $WEED.ca $CL.ca $HEXO.ca $RWB.ca

8 Small Cap #Cannabis Companies That Will Lead The Next Growth Cycle For The $97 Billion Market By 2026 $AVCN.ca $CBDT.ca $HBOR.ca $HOLL.ca $INNO.ca $SPDR.ca $TBI.ca $TCAN.ca

Posted by AGORACOM-JC at 3:39 PM on Thursday, October 8th, 2020

Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:

  1. Cannabis legalization is gaining momentum around the world.
  2. Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
  3. It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).

So what is this going to translate into?

The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92% (Fortune Business Insights)

WHY WILL THIS TIME BE DIFFERENT?

Big promises, big IR budgets, big hype …. Big Letdown.

That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.

Investors will remember that the same thing happened during the dot-com era.  As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.

But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses.  What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.

The same thing is about to happen to the Cannabis sector

Meet the 8 new horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).

Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year.  These are the only known CBD cosmetics backed by clinical trials.

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

For more information about the company, please check out the Avicanna HUB on AGORACOM.

Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for … but then these numbers recently came in for the first two quarters to further cement Empower as a leader:

PatientVisits

  • Q1 + 377% To 5,717
  • Q2 + 56% To 6,696

Revenues $USD

  • Q1 + 416% To $790,000 (NO COVID)
  • Q2 + 56% To $923.000

TOTAL Q1 AND Q2

  • REVENUE                 $1.7M vs $745K         = + 130%
  • PATIENTS                 12,400 vs 5,500           = + 125%
  • NET LOSS                 $920K vs 1.85M         = – 50% 

Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019. 

BONUS – The Company’s physician staffed clinics have are also generating significant revenue and growth from the COVID-19 pandemic as follows: 

  • Increased CBD treatments from patients suffering increased anxiety;
  • Testing for individuals and families
  • Testing for local businesses and employees 
  • Testing for enterprise level organizations across the country 
  • Acquisition of an 8,000 sq ft lab in Dallas that can process 4,000 COVID-19 tests per day
    • At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY

Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.  Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.

For more information about the company, please check out the Empower HUB on AGORACOM.

Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006.  We thought that would get your attention.

What Do They Do?

HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:

1. Retail Dispensaries

2. Wholesale

3. Cultivation and Processing

HIGHLIGHTS

  • Founded in 2006. One of the oldest and most respected cannabis retailers in California
  • Awarded one of the first six medical cannabis licenses in the USA
  • Operations have generated over $400M in cumulative sales since inception
  • Retail operations command 3% of California’s entire retail market
  • 2020 Financials (Q1 +  Q2)

○       Revenues         $30,800,000

○       Gross Profit     $14,000,000

○       EBITDA            $1,100,000

  • Expected to generate approximately $62M – $65M in sales in 2020
  • Operate California’s only drive-through dispensary 
  • Over 1,300 customers per day in Q2
  • Oakland dispensary is one of the largest retail cannabis locations in the world
  • 2020E Guidance
    • ~$44M Retail Revenue
    •   ~$21M Wholesale Revenue
    • ~$62M – ~65M Total Revenue

For more information about the company, please check out the Harborside Inc  hub on AGORACOM.

Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:

  • Revenues $USD
    • Q1 +317%  YoY to $862,000
    • Q2 +3685% YoY to  $8,500,000
  • TOTAL Q1 AND Q2
    • REVENUE                 $9.4M vs $428K     = + 2096%
    • GROSS PROFIT        $1.2M vs ($133K)   = + 1002%

In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:

Hollister is also the creator of California’s most hash-infused pre-roll HashBone

For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

  1.  PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
  2. CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
  3. OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.

Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.

  1. SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
  2. SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
  3. SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.

For more information about the company, please check out the Spyder Cannabis  hub on AGORACOM.

Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle. 

  • Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
  • Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
  • Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
  •  Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.

We’ll let these revenue numbers speak for themselves.

  • August 2020 CAD $3,809,000
  • July 2020 CAD $2,340,000
  • June 2020 CAD $2,712,000

The above represents an increase of 19%, over the same period in 2019.

QUARTERLY REVENUE $CAD

  • Q1 $7,600,000 Growth
  • Q2  $12,800,000 Growth 

TOTAL Q1 AND Q2

  • REVENUE  $20,400,000
  •  GROSS PROFIT  $2,154,357

The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.

The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.

For more information about the company, please check out the Thoughtful Brands hub on AGORACOM. 

TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.

  • CAD $24.9M  Revenue Run Rate from 10,000 sq.ft  test facility
  • CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
  • Acquired two California companies,
  • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented 
  • Direct to dispensary model, cutting out the middleman

 REVENUES  $CAD

  • Q1  $906,000
  • Q2  $4,300,000

 TOTAL Q1 AND Q2

  • REVENUE     $5,206,000    
  • GROSS MARGIN $1,920,000

For more information about the company, please check out the TransCanna hub on AGORACOM.

Thanks for reading and discovering these great small cap cannabis companies.  Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:

https://agoracom.com/portal/Small-Cap-Marijuana-Cannabis-Stocks

Tags: , , , , , , , ,
Posted in AGORACOM Small Cap Stocks For Investment, All Recent Posts, Avicanna Inc., Empower Clinics Inc., Featured, Hollister Biosciences, Innocan Pharma Corporation, Spyder Cannabis Inc., Thoughtful Brands Inc., TransCanna Holdings Inc. | Comments Off on 8 Small Cap #Cannabis Companies That Will Lead The Next Growth Cycle For The $97 Billion Market By 2026 $AVCN.ca $CBDT.ca $HBOR.ca $HOLL.ca $INNO.ca $SPDR.ca $TBI.ca $TCAN.ca

TransCanna’s $TCAN.ca Crop Management Services Division Celebrates Breaking Ground at its First Managed Facility $CGC $ACB $APHA $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:13 AM on Thursday, October 8th, 2020
tcan-square
  • Provides update regarding the deployment of Lyfted Farms’ Crop Services Management Division (or “LFCSMD”) and the contractual agreement to manage the multi-acre commercial cannabis greenhouse facility in Stanislaus County, CA on behalf of Central Valley Growers (previously announced April 21, 2020)
  • Construction has commenced in Patterson, California, for a new 22,000 sq.ft. cultivation facility to be managed and operated by LFCSMD
  • “This is an additional revenue vertical that we intend to perfect and expand, we are very excited to work with the Central Valley Growers team and build a mutually prosperous business”, said TransCanna CEO Bob Blink

Vancouver, British Columbia–(October 8, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to provide an update regarding the deployment of Lyfted Farms’ Crop Services Management Division (or “LFCSMD”) and the contractual agreement to manage the multi-acre commercial cannabis greenhouse facility in Stanislaus County, CA on behalf of Central Valley Growers (previously announced April 21, 2020). Operating under the wholly-owned subsidiary, Lyfted Farms Inc., construction has commenced in Patterson, California, for a new 22,000 sq.ft. cultivation facility to be managed and operated by LFCSMD.

LFCSMD is very pleased to announce the finalized contract with Central Valley Growers to be the sole operator and distributor for the new state of the art facility. The first phase of operations is scheduled to OPEN January 1, 2021.

“This is an additional revenue vertical that we intend to perfect and expand, we are very excited to work with the Central Valley Growers team and build a mutually prosperous business”, said TransCanna CEO Bob Blink, “Lastly, I am very proud of all parties for staying engaged through the current COVID 19 pandemic, working through the challenges to keep this opportunity moving forwards”, Blink adds.

Central Valley Growers CEO Nav Singh remarks, “we are very excited to see the execution of our partnership with Lyfted Farms, they have an outstanding reputation for cultivating in-demand genetics, and it creates more certainty once product is ready for market.” LFSCMD ‘Higher Standard Farm Management Agreement’ includes the provision of genetic stock, crop cultivation, labor, compliance oversight, and distribution of finished product over an initial 5-year term.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, TransCanna Holdings Inc. | Comments Off on TransCanna’s $TCAN.ca Crop Management Services Division Celebrates Breaking Ground at its First Managed Facility $CGC $ACB $APHA $CRON.ca $OGI.ca

VIDEO – Empower Clinics $CBDT.ca Acquires Testing Lab And Lands First COVID-19 Testing Contract For Major Film & TV Studio $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 6:42 PM on Wednesday, October 7th, 2020

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for … but then these numbers came in for the first two quarters:

Revenues $USD 1.7M vs $745,000 = 130% Gain

Patient Visits 12,400 vs 5,500 = 125% Gain

CBDT has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.

But he is far from done.

In the last 36 hours, Empower announced:

1.  The acquisition of an 8,000 sq ft lab in Dallas (they do everything big over there) that can process 4,000 COVID-19 tests per day.  At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.  We will let you do the math with the combination of higher prices + more tests per day.

2.  An agreement to run 1,000 COVID-19 RT-PCR Tests for a major film & TV studio, which could lead to much more business if all goes well with this first batch. To this end, the lab has already processed tests for six different film and television productions since September 1st (prior to the acquisition) and continues to build both confidence and credibility within the industry.

It doesn’t take much to see that the lab has the potential to take Empower to a whole new level.  Specifically, if you’re an investor in Well Health (WELL:TSX) and/or CloudMD (DOC:TSXV) you have to start taking a serious look at Empower as the next great potential health and wellness company.  It’s already proven solid revenues and growth from its clinics, is expanding its telemedicine practice very nicely and now has the power to quickly generate significant enterprise level revenues from its newly acquired medical diagnostics laboratory … which is already bearing fruit just 24 hours after the acquisition.

Can McAuley pull it off?  First consider what he has already accomplished after inheriting a catastrophe of a company in early 2019.  Secondly, McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth through Q2 2020 … with some jet fuel now added here in Q4.

And if you MISSED Well Health and CloudMD, you really need to take a close look at Empower as the next great small cap health & wellness company.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , , , , ,
Posted in AGORACOM Via Satellite, Empower Clinics Inc., Featured | Comments Off on VIDEO – Empower Clinics $CBDT.ca Acquires Testing Lab And Lands First COVID-19 Testing Contract For Major Film & TV Studio $VPT.ca $ADK.ca

MEDIA: Augmented Reality #AR Takes Sports Engagement to the Next Level – ImagineAR $IP.ca $IPNFF $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 2:25 PM on Wednesday, October 7th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

ImagineAR Inc. (CSE: IP, OTCQB: IPNFF, Forum) is a developer of augmented reality, (AR), platforms that are proving to be transformative for how we engage – and experience – immersive digital marketing campaigns.

This Canadian AR Company recently signed a five-year partnership with the National Football League’s AlumniAcademy to create a custom platform for the Academy to engage and activate players, coaches, and sponsors to connect with football fans around the globe. Adding to this news, the Company just signed a two-year partnership agreement with Valencia CF of Spain’s La Liga league, one of the biggest soccer clubs in the world with seven million social media followers. There is a lot to digest here, and we are joined by Imagine AR CEO Allen Paul Silverrstieen to find out more ….

Click here to download the episode.

SH: Thank you for joining us. The Imagine AR platform has immense applications for any business or a sports organization to instantly create their own AR mobile campaigns. So, in general terms, can you just run us through how this works?

APS: Absolutely. We we’ve invested over the years into a self-service AR platform, this AR platform, augmented reality, as you mentioned, allows any company, any business, any person to create an immersive experience on a digital phone targeting either consumers or we specialize also in sports to their fans. So this platform allows companies or teams to utilize their existing content, whether it be movies, images, coupons, whatever, and engage consumers directly in their handset and with today’s environment, a COVID-19, it’s a safe and healthy way with social distancing to excite people, get them involved, build a community and ultimately drive revenue.

SH: So many sports experiences are now virtual. Like you said, a given social distancing guidelines, this could soon become the new norm, correct?

APS: Oh, absolutely. And as you can see from our recent deals, including LA Liga’s team Valencia, they have over 7 million fans worldwide and COVID is certainly impacted them in terms of having any fans in stadium. So, they were looking for an engagement tool to build a community, drive sponsorship revenue, and to keep building out their reputation, their brand. So, Franco Segarra, who is their CIO, we met through, uh, the GSSC, which is a Microsoft sport organization in Spain. He understood AR ready. So, what we did with our platform and immediately saw the opportunity similar to that, you said, it’s going to be the norm. So that is something we’re implementing with him, our AR SDK, which is a software development kit. So our entire augmented reality platform immediately integrates with their existing platform to allow their fans, to share these experiences in social and fully integrating building rewards and other kind of re uh, I guess, programs, custom programs within the RAF and their fans. And it is something we’re pursuing here in North America, which we just announced, as you mentioned, the NFL alumni, starting with the Academy, but also work with a number of other teams as well.

SH: The Academy has a huge task to fill hundreds of vacant spots over a season, all due from injuries. Uh, this really seems to streamline the process.

APS: Yes, we, we do two things with the NFL alumni. It’s a five-year revenue partnership deal. Initially they have the Academy, which they want to be like the minor leagues of NFL. So really between the division one and top colleges and their talent and the NFL to have players who may not be on the roster, but are NFL ready? The Academy just started up and running this week. They’ve got a full camp they’re hand selected. I think it’s somewhere around the mid twenties and players, and we’re providing activations in the locale for them, for the coaches, and then taking it as they continue forward into the NFL. So, it’s a way to really provide a communication platform for these players, as well as most importantly, for the NFL Academy to engage fans as well as the community, as they continue forward. Additionally, imagine you are built a custom platform for the Academy that allows all 32 NFL teams to access. So, when they are looking for a player, whether it’s offense or defense, they can access our platform. We custom built for the Academy, see the videos of players, see the reviews, the comments, and then select players based on what they see. So it’s really an entire religion of that. Initially is going to start with the alumni in the Academy, but we see it growing further with all the chapters they have over 30 plus chapters throughout the United States with players and build out new AR activations with very famous and former players throughout the United States.

SH: Imagine AR also recently appointed a former Portland Trailblazers, CIO, Chris dill, as an advisor to bring your platform to professional sports teams like this. Uh, can we expect more partnerships like this? Like the one with the NFL in the future?

APS: Oh, absolutely. And that’s a good question. So, Chris dill, having him join was a big step for us crystal. I met him about a year and a half at a conference. We were both speaking at, he actually was a moderator. He is really considered one of the top sports tech people in North America. And we’ve been speaking over a year and a half into him. Finally, come in, join our team as an advisor and work with us is a real vote of confidence and validation of our augmented reality platform for the sports industry. We expect to continue to grow with him and his relationships and have partnerships like the NFL alumni like we have with Valencia and through 2020 and beyond to build out sports. But we will be going into other areas. Our platform has the ability to apply, whether it be retail, whether it be property owners, whether it be publishing any type of environment. So, we do expect partnerships similar to the ones we did to date that we’ve announced, which are revenue sharing partnerships over long-term as well as into new vertical markets.

SH: Like we spoke about at the top. Uh, you just signed a two-year agreement with Valencia CF to become an innovation partner and provide your AR platform for a fan activation and engagement. So, being such a popular soccer club, uh, what opportunities could this create for your company?

APS: Well, having them involved, Valencia was a big win for us. A it brought us into Europe, certainly into Spain as well. Obviously, the LA Liga, the league of which Valencia is a part of is significant, has lots of teams and millions and millions and hundreds of millions of fans everywhere. And I think Valencia will become our premier client like the first reference accounts. So we expect it to grow from getting them up and running successful as our proven case to really go into other soccer organizations, not only in Spain, but throughout Europe and the rest of the way,

SH: Bringing sports clubs closer to their fans and introduce these unique experiences, could potentially be applied to just about any sports club.

APS: It’s all about engagement and community. And when you look at sports and certainly, with COVID, a tremendous health issue that we’re going to be facing for certainly the next year, if not longer. And bringing fans back in a stadium teams, got to engage. These fans, keep them excited about the team, keep them updated, build a community. And ultimately at the end of the day, it’s drive revenue. Our augmented reality platform imagine they are. And the SDK allows the teams to engage their fans and sell merchandise, offer discounts and offer unique experiences that can be brought right into the home as well. So we’re excited for starting with sports, but we think sports is going to bring us, the brands is going to bring us other opportunities and other vertical markets, again, not only here in North America, but around the world. And augmented reality is expected to grow significantly. There’s a lot of analysts out there. We follow one analyst in particular, Digi Capitalist. They said, despite COVID 19, they expect the existing market of AR, which is $4 billion to grow to 48 billion in four years. So, we do see a lot of major growth for our platform that we’ve invested in, built in here with sports, but also into entertainment and other areas.

SH: I wanted to ask you about that. When you envision the future of augmented reality and marketing, just as an industry in general, what do you picture?

APS: I think as we go further, mobile AR will continue to grow and expand. You’ve got major companies like Snapchat snap that does a tremendous amount of AR Facebook has gotten in Instagram, has gotten in. So the education hurdles being overcome, there’s a lot of uses and they are, that are starting to grow and out there. This is a big market opportunity in a couple of years, as we’ve heard, and maybe even sooner, uh, Apple’s going to come out with Apple AR glasses. Facebook is committed to Facebook AR glasses. That’s going to be the paradigm shift when people start putting on glasses, which will be tied to their phones through Bluetooth and have AR activations visually wherever they go, whether they’re walking through the middle of a city, they see advertisements, they could see movie trailers have the opportunity to purchase tickets while they’re doing that as well.

That’s going to be the, the real future. And Tim cook, CEO of Apple has been quoted multiple times and conferences. And even most recently, I believe in Ireland, uh, early the Sierra that he believes AR will be the next big thing, just like the mobile phone. So, our expectations are extremely big. We see exponential growth out there. We have a really tight and big sales pipeline and is growing as we speak. And we’re pretty optimistic for our future as the only pure play augmented reality tech company in the market for investors today in North America and around the

SH: Thank you for joining us today, to talk about all things AR in the NFL. It’s really exciting to hear about what you’ve accomplished and what you have coming.

APS: Thank you very much. We appreciate you taking the time. And, uh, we look forward to having the opportunity maybe to speak in a while and discuss some more of the deals and opportunities that we’re bringing to market. Thank you and be safe.

Source: https://stockhouse.com/opinion/interviews/2020/10/05/augmented-reality-takes-sports-engagement-to-next-level

Tags: , , , , , , , , , , , , , , ,
Posted in Imagine AR | Comments Off on MEDIA: Augmented Reality #AR Takes Sports Engagement to the Next Level – ImagineAR $IP.ca $IPNFF $SEV.ca $VST.ca $YDX.ca $NTAR.ca

ImagineAR $IP.ca $IPNFF Supports Chef Claudy Pierre’s for E.A.T. Initiative & 2020 World Food Day Celebration $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 7:09 AM on Wednesday, October 7th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

ImagineAR Supports Chef Claudy Pierre’s for E.A.T. Initiative & 2020 World Food Day Celebration

  • Providing its augmented reality self-service platform to support Chef Claudy Pierre’s E.A.T. Initiative program in partnership with Pittsburgh Gateways’ Energy Innovation Center (EIC) in Pittsburgh, Pennsylvania
  • During this pandemic, Pierre has started providing food to the community from the EIC Kitchen and has donated over 30,000 meals and Blessing Boxes, thanks to the support of the EIC and corporate partners such as Chime Bank and Super Bakery.

VANCOUVER, BC and ERIE, Pa., Oct. 7, 2020 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) is providing its augmented reality self-service platform to support Chef Claudy Pierre’s E.A.T. Initiative program in partnership with Pittsburgh Gateways’ Energy Innovation Center (EIC) in Pittsburgh, Pennsylvania. During this pandemic, Pierre has started providing food to the community from the EIC Kitchen and has donated over 30,000 meals and Blessing Boxes, thanks to the support of the EIC and corporate partners such as Chime Bank and Super Bakery.

“Since the beginning of the pandemic we have been able to serve local residents over 30,000 meals,” said Pierre. “AR provides us an innovative way to tell our EIC story and recognize corporate partners like Chime Bank. ImagineAR technology is really cool, and the community reaction has been overwhelming.”

The ImagineAR program includes using the ImagineAR app to deliver a motivational video message about the program and an interactive 3D AR mascot of Pierre. Recently, recipients of the Blessing Boxes were asked to download the ImagineAR app and scan the Blessing Boxes logo to instantly experience the motivational video on their mobile phone. In addition, the 3D mascot of Pierre will be used for social media programs to extend community awareness.

Neal Bendesky, Vice President of Sales for ImagineAR, said, “We are proud to support the EIC and Chef Claudy for their community outreach program. Chef Claudy’s commitment as a stakeholder in Pittsburgh is the type of leadership that represents necessary strides in our country. We’re excited to utilize his 3D AR image to create social media activations and build the EIC’s AR community.”

The EIC and ImagineAR partnership was recently developed by former 15-year NFL quarterback Gus Frerotte, who houses his media production unit at the EIC. Frerotte, Bendesky and ImagineAR CEO Alen Paul Silverrstieen, along with Robert Meeder, President and CEO of Pittsburgh Gateways Corporation and the EIC, are supporting Pierre’s community outreach as a start to introducing trending technology like AR to support local and regional businesses.

“Chef Claudy is a hometown hero, and we hope other corporations rally around his efforts during these uncharted times,” added Frerotte.

On October 16, 2020, the E.A.T. Initiative will host the 2020 World Food Day Celebration as the City of Pittsburgh’s official acknowledgement of the 75th Anniversary of World Food Day, hosted by the United Nation’s Food & Agriculture Organization.

About Pittsburgh Gateway
Pittsburgh Gateways Corporation’s mission is to provide strategic planning, development and direct management assistance for communities, community-based economic development organizations, research & academic institutions and private entities seeking the acceleration of technology-based businesses. Incorporated into this mission is our goal to combat community deterioration in the City of Pittsburgh and other economically distressed areas of Pennsylvania. Pittsburgh Gateways Corporation is registered as a 501(c)(3) non-profit organization. For more information, visit www.pghgateways.org/.

About ImagineAR

Imagine AR Inc. (CSE: IP) (OTC: IPNFF) has developed ImagineAR.com; an “AR-as-a-Service” platform for desktops that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds using ImagineAR. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage with videos, information, advertisements, coupons, 3D holograms and any interactive content, all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The ImagineAR.com mobile app is available in the IOS and Android mobile app stores. The platform is available as a native mode SDK. For more information or to explore working with ImagineAR, please visit www.imaginear.com.

All trademarks of the property of respective owners.
ON BEHALF OF THE BOARD
Alen Paul Silverrstieen
President & CEO
(818) 850-2490

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if ImagineAR Entertainment Inc. (CSE: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Featured, Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Supports Chef Claudy Pierre’s for E.A.T. Initiative & 2020 World Food Day Celebration $SEV.ca $VST.ca $YDX.ca $NTAR.ca

PyroGenesis $PYR.ca Files Application to Uplist to #TSX as a Technology Company $RTN $NOC $UTX $DDD.ca

Posted by AGORACOM-JC at 3:13 PM on Tuesday, October 6th, 2020
  • Announce that it has applied to have its common shares listed on the Toronto Stock Exchange, as a technology Company
  • Upon receiving conditional approval from the TSX, the Company will consider, based on market conditions at the time, if it will proceed in due course
  • In the interim, the Company has, and will, file the appropriate documents and take all other measures to be in position to act quickly should the opportunity to up-list be acceptable to the Board of Directors

MONTREAL, Oct. 06, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products,  is pleased to announce that it has applied to have its common shares listed on the Toronto Stock Exchange (“TSX”), as a technology Company.

Listing is subject to the approval of the TSX in accordance with its original listing requirements for technology companies. The TSX has not conditionally approved the company’s listing application and there is no assurance that the TSX will approve the listing application. Without limitation, the original listing requirements of the TSX provide that a company must have a minimum of $10,000,000 in the treasury, the majority of which has been raised by the issuance of securities qualified for distribution by a prospectus, which requirement is not currently satisfied by the company.

“We are proud to announce today that the Board of Directors of PyroGenesis, believing  that the Company is at a stage where investors could benefit from an up-listing to a more senior exchange, has taken, and is taking, steps to do just that,” said P. Peter Pascali, CEO of PyroGenesis Canada Inc. “Although the Company does not need to raise cash for working capital purposes it does not, as noted, have on its balance sheet the requisite funds raised by prospectus which is mandated by the TSX for any company that wants to be listed as a technology company.  Upon receiving conditional approval from the TSX, the Company will consider, based on market conditions at the time, if it will proceed in due course.  In the interim, the Company has, and will, file the appropriate documents and take all other measures to be in position to act quickly should the opportunity to up-list be acceptable to the Board of Directors. Notwithstanding our sincere desire to up-list, there is no guarantee that either the TSX will approve the listing application or that the market conditions at the time of approval will be acceptable to the Board. Should for any reason the up listing not be pursued, we would consider that a material change which would be press released immediately.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

Tags: , , , , , , , , , ,
Posted in PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Files Application to Uplist to #TSX as a Technology Company $RTN $NOC $UTX $DDD.ca

Else Nutrition $BABY.ca Announces Closing of $20.7 Million Upsized Bought Deal Public Offering and Concurrent $5 million Private Placement $BMY $ABT $TSN $CAG

Posted by AGORACOM-JC at 10:07 AM on Tuesday, October 6th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Closed its previously announced upsized bought deal public offering of units for ‎aggregate gross proceeds of approximately CAD$20.7 million, including the exercise of the over-allotment option in full
  • The Company issued ‎‎9,200,000 Units at a price of CAD$2.25 per Unit, each Unit consisting of one common share of the ‎Company and one-half of one common share purchase warrant, with each whole warrant entitling the holder to purchase one Share at the price of CAD$3.25 per Share until October 6, 2022
  • In total, the Company received gross proceeds of approximately CAD$25.7 million from the closing of the Offering and Private Placement

VANCOUVER, BC / October 6, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), is pleased to announce that it has closed its previously announced upsized bought deal public offering of units (the “Units“) for ‎aggregate gross proceeds of approximately CAD$20.7 million, including the exercise of the over-allotment option in full (the “Offering“). The Company issued ‎‎9,200,000 Units at a price of CAD$2.25 per Unit, each Unit consisting of one common share of the ‎Company (a “Share“) and one-half of one common share purchase warrant, with each whole warrant (a “Warrant“) ‎entitling the holder to purchase one Share at the price of CAD$3.25 per Share until October 6, 2022. ‎The Company has received approval from the TSX Venture Exchange (“TSXV“) to list the Warrants issued pursuant to the Offering, and the Warrants are expected to be listed and posted for trading on the TSXV under the ticker symbol “BABY.WT” effective on or about October 8, 2020.

Concurrent with the Offering, the Company issued 2,224,111 Units on a private placement basis, for additional gross proceeds of approximately CAD$5 million (the “Private Placement“). New H2 Limited (“New H2“), a wholly owned subsidiary of Health and Happiness (H&H) International Holdings Ltd, a Hong Kong Stock Exchange company (HK:1112), subscribed for CAD$4,000,000 worth of Units in the Private Placement pursuant to a previously disclosed investor rights agreement dated March 2, 2020 between the Company and New H2.

In total, the Company received gross proceeds of approximately CAD$25.7 million from the closing of the Offering and Private Placement.

The Offering was conducted on a bought deal basis by Canaccord Genuity Corp. and Haywood ‎Securities Inc. (collectively, the “Underwriters“). On closing, the Company issued to the Underwriters an aggregate ‎of 597,920 broker warrants (the “Broker Warrants“), each Broker Warrant entitling the holder to ‎purchase one Share at the price of CAD$2.25 per Share until October 6, 2022.‎

The Units issued pursuant to the Offering were offered by way of a short form prospectus filed in all provinces of Canada except Quebec and elsewhere on a private placement basis. The Company intends to use the net proceeds of the Offering and the Private Placement for marketing, distribution, inventory and general corporate purposes.

All securities issued in connection with the Private Placement are subject to a four month hold period pursuant to the policies of the TSX Venture Exchange and applicable securities laws.

The securities offered have not been, nor will they be, registered under the U.S Securities Act of 1933 (the “U.S. Securities Act“) or any ‎state securities laws, and may not be offered or sold in the United States or to, or for the account or ‎benefit of, any person in the United States or to U.S. Persons (as such term is defined in Regulation S ‎under the U.S. Securities Act) absent registration or an applicable exemption from the registration ‎requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy ‎nor will there be any sale of the securities in any state in which such offer, solicitation or sale would be ‎unlawful.‎

MI 61-101

New H2’s subscription for Units in the Private Placement constitutes a “related party transaction” within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). The transaction is exempt from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a) as the fair market value of the related party’s subscription will not be more than 25% of the Company’s market capitalization. The Company will be filing a material change report in respect of the related party transaction on SEDAR less than 21 days prior to the closing of the transaction due to the fact that the Company wished to close the transaction as soon as possible.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed on the TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For additional information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements relating to the trading date of the Warrants and the intended use of the net proceeds of ‎the Offering and the Private Placement. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

Tags: , , , , , , , , , , ,
Posted in Else Nutrition Holdings Inc., Featured | Comments Off on Else Nutrition $BABY.ca Announces Closing of $20.7 Million Upsized Bought Deal Public Offering and Concurrent $5 million Private Placement $BMY $ABT $TSN $CAG

« Older Entries
Newer Entries »